logo
logo
Concentra Group Holdings Parent, Inc.

Concentra Group Holdings Parent, Inc.

NYSE•CON
CEO: Mr. William Keith Newton
セクター: Healthcare
業種: Medical - Equipment & Services
上場日: 2010-05-25
Concentra Group Holdings Parent, Inc. provides occupational health services in the United States. The company offers occupational and consumer health services, including workers' compensation injury care, urgent care, clinical testing, preventative care, and employer services, as well as wellness programs through occupational health centers and onsite clinics. It also provides Concentra Telemed, a telemedicine solution for the treatment of work-related injuries and illnesses, and employer services; pharmacy solution under the Concentra Pharmacy name; and Concentra Medical Compliance Administration, a third-party administrator that helps to manage abuse testing programs for employers with regulated or non-regulated workforces. The company was founded in 1979 and is based in Mechanicsburg, Pennsylvania. Concentra Group Holdings Parent, Inc. is a subsidiary of Select Medical Corporation.
連絡先情報
4714 Gettysburg Road, PO Box 2034, Mechanicsburg, PA, 17055, United States
717-972-1100
www.concentra.com
時価総額
$3.02B
PER (TTM)
17.8
38.3
配当利回り
1.1%
52週高値
$24.69
52週安値
$18.55
52週レンジ
81%
順位41Top 44.9%
4.0
F-Score
改良版 Piotroski 分析
4年ファンダメンタル
堅調 • 4 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2022-2025

財務ダッシュボード

Q4 2025 データ

売上高

$539.10M-100.00%
直近4四半期の推移

EPS

$0.29+70.59%
直近4四半期の推移

フリーCF

$0.00+0.00%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Revenue Growth Nine Months Revenue $1.62B YTD, up 13.2% for nine months ended September 30, 2025, driven by volume and acquisitions.
Net Income Attributable Growth Net income attributable to Company $49.8M Q3 2025, showing improvement from $44.3M reported in Q3 2024.
Major Acquisitions Completed Completed Nova ($265.0M) and Pivot Onsite ($54.4M) acquisitions, expanding onsite clinic footprint significantly in 2025.

リスク要因

Ongoing Litigation Exposure Ongoing litigation including data breach lawsuits and DOJ physical therapy billing investigation pose potential liabilities.
Labor Cost Inflation Pressure Labor intensive industry faces rising wage expenses due to inflation and persistent labor shortages impacting margins.
Variable Interest Rate Risk Variable rate debt exposes interest expense to market rate fluctuations, partially mitigated by derivative contracts.

見通し

Debt Repayment Activity Made $35.0M voluntary repayment on Revolving Credit Facility in October 2025; availability remains strong at $428.0M.
Shareholder Capital Return Board authorized $100M share repurchase program funded by cash on hand, authorization expires December 31, 2027.
Interest Rate Hedging Strategy Derivative contracts limit variable interest rate exposure on term loan principal through February 29, 2028.

同業比較

売上高 (TTM)

Bausch Health Companies Inc.BHC
$10.03B
+5.9%
Organon & Co.OGN
$6.22B
-2.9%
DENTSPLY SIRONA Inc.XRAY
$3.62B
-7.1%

粗利益率 (最新四半期)

Acadia Healthcare Company, Inc.ACHC
96.4%
+0.1pp
Catalyst Pharmaceuticals, Inc.CPRX
82.9%
-2.1pp
Bausch Health Companies Inc.BHC
72.0%
-0.2pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
PBH$3.21B17.110.2%30.9%
CON$3.02B17.851.2%0.0%
ITGR$3.01B34.75.2%38.6%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
2.5%
緩やかな成長
4四半期純利益CAGR
-2.4%
収益性の安定
キャッシュフロー安定性
75%
キャッシュフローの変動が大きい

深度リサーチ

次回決算:2026年2月26日
|
EPS:$0.22
|
売上高:$532.00M
財務レポート
財務データ
全年度
  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月6日|
    売上高: $572.80M+17.0%
    |
    EPS: $0.38+8.6%
    予想通り
  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月7日|
    売上高: $550.79M+15.2%
    |
    EPS: $0.35-14.6%
    予想を下回る
  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月7日|
    売上高: $500.75M+7.1%
    |
    EPS: $0.31-20.5%
    予想通り
  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月3日|
    売上高: $1.90B+3.4%
    |
    EPS: $1.30-8.5%
    予想を上回る
  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月6日|
    売上高: $489.64M+3.3%
    |
    EPS: $0.35-16.7%
    予想通り
  • Form 10-Q - Q2 2024

    会計期末: 2024年6月30日|提出日: 2024年8月27日|
    売上高: $477.92M+2.3%
    |
    EPS: $0.41-2.4%
    予想を下回る